Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)

Phase 1

Completed

Conditions: Myeloma

First Posted Date: 2011-01-19

Last Posted Date: 2016-04-13

Lead Sponsor: Nantes University Hospital

Target Recruit Count: 72

Registration Number: NCT01279694

Locations: 🇫🇷
CHU de Nantes, Nantes, France

Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone Acetate
Drug: Prednisone
Drug: Dasatinib
Drug: Sunitinib

First Posted Date: 2010-12-07

Last Posted Date: 2023-12-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 190

Registration Number: NCT01254864

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Hodgkin Lymphoma

Interventions: Drug: Bleomycin
Drug: Etoposide
Drug: Doxorubicin
Drug: Vinblastine
Drug: Cyclophosphamide
Drug: Dacarbazine
Drug: Vincristine
Drug: Procarbazine
Drug: Prednisone

First Posted Date: 2010-12-01

Last Posted Date: 2015-08-13

Lead Sponsor: Fondazione Michelangelo

Target Recruit Count: 331

Registration Number: NCT01251107

Locations: 🇮🇹
Fondazione IRCCS Istituto Nazionale di Tumori di Milano, Milano, Italy

Single Oral Dose of Dexamethasone Versus Five Days of Prednisone in Adult Asthma

Phase 4

Completed

Conditions: Asthma
Reactive Airway Disease

Interventions: Drug: Dexamethasone
Drug: Prednisone

First Posted Date: 2010-11-16

Last Posted Date: 2016-01-07

Lead Sponsor: Alameda County Medical Center

Target Recruit Count: 376

Registration Number: NCT01241006

Locations: 🇺🇸
Alameda County Medical Center, Oakland, California, United States

Methotrexate as a Steroid-sparing Agent in Idiopathic Retroperitoneal Fibrosis: a Randomised, Multicenter Trial

Phase 3

Conditions: Idiopathic Retroperitoneal Fibrosis
Perianeurysmal Retroperitoneal Fibrosis
Chronic Periaortitis

Interventions: Drug: Prednisone
Drug: Methotrexate+Prednisone

First Posted Date: 2010-11-15

Last Posted Date: 2010-11-15

Lead Sponsor: University of Parma

Target Recruit Count: 200

Registration Number: NCT01240850

Locations: 🇮🇹
Nephrology Unit, University Hospital of Parma, Parma, Italy

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Revlimid
Drug: Melphalan
Drug: Dexamethasone
Drug: Prednisone
Drug: Velcade

First Posted Date: 2010-11-09

Last Posted Date: 2017-01-18

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 250

Registration Number: NCT01237249

Locations: 🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸
Hospital Ramón y Cajal, Madrid, Spain
🇪🇸
Hospital Clínico de Valencia., Valencia, Spain

and more 60 locations

Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Biological: Adalimumab
Drug: Prednisone
Drug: Azathioprine

First Posted Date: 2010-11-05

Last Posted Date: 2018-01-16

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 252

Registration Number: NCT01235689

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Phase 1

Completed

Conditions: Castrate-Resistant Prostate Cancer

Interventions: Drug: ISIS EIF4E Rx
Drug: Prednisone
Drug: Docetaxel

First Posted Date: 2010-11-04

Last Posted Date: 2023-10-06

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 113

Registration Number: NCT01234025

Locations: 🇺🇸
Fort Range Cancer Center, Fort Collins, Colorado, United States
🇺🇸
St. Luke's - Roosevelt Hospital Center, New York, New York, United States
🇵🇱
Clinical Oncology Department and Day Hospitalization Unit, Independent Public Healthcare Facility T. Koszarowski Opolskie Oncology Centre in Opole, Opole, Poland

and more 35 locations